Status:
COMPLETED
Interaction of Melatonin With MTNR1B Genotype on Glucose Control - Study 2
Lead Sponsor:
Brigham and Women's Hospital
Collaborating Sponsors:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions:
Glucose
Circadian Rhythm
Eligibility:
All Genders
21-55 years
Phase:
NA
Brief Summary
This project aims to test the impact of melatonin and MTNR1B variation on regulation glucose regulation in a highly controlled in-laboratory setting and ex vivo in pancreatic islets.
Detailed Description
The investigators' recent GWAS discovery of MTNR1B as a novel type 2 diabetes gene has sparked great interest into the role of melatonin in glycemic control, for which the mechanism is largely unknown...
Eligibility Criteria
Inclusion
- Body Mass Index: 20 and 35 kg/m2
- Age: 21-55 years of age
- Caucasian
- Non-smoking
- With regular sleep-wake cycle
- Passed medical and psychological screening tests
Exclusion
- Acute, chronic or debilitating medical conditions
- History of neurological or psychiatric disorder
- History of sleep disorder or regular use of sleep-promoting medication
- Current prescription, herbal, or over-the-counter medication use
- Traveling across 2 or more time zones within past 3 months
- Worked night or rotating shift work within past 1 year
- Drug or alcohol dependency
Key Trial Info
Start Date :
February 17 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 19 2022
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT03464084
Start Date
February 17 2018
End Date
July 19 2022
Last Update
July 26 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115